达可替尼

{{Infobox drug
| image = Dacomitinib.svg
| alt =
| caption =

| pronounce =
| tradename = Vizimpro
| Drugs.com =
| MedlinePlus = a618055
| DailyMedID = Dacomitinib
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = 口服
| class =
| ATCvet =
| ATC_prefix = L01
| ATC_suffix = EB07

| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =
| legal_DE =
| legal_NZ =
| legal_UK =
| legal_US = Rx-only
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN =
| legal_status = Rx-only

| bioavailability = 80%
| protein_bound = 98%
| metabolism = CYP2D6、CYP3A4
| metabolites = O-去甲基达可替尼
| onset =
| elimination_half-life = 70小时
| duration_of_action =
| excretion = 79%分辨、3%尿液

| index2_label = as salt
| CAS_number_Ref =
| CAS_number = 1110813-31-4
| PubChem = 11511120
| DrugBank = DB11963
| ChemSpiderID = 9685914
| UNII_Ref =
| UNII = 2XJX250C20
| KEGG = D09883
| KEGG2 = D10514
| ChEBI = 132268
| ChEMBL = 2105719
| IUPHAR_ligand = 7422
| NIAID_ChemDB =
| PDB_ligand = 1C9
| synonyms = PF-00299804

| IUPAC_name = (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
| C=24 | H=25 | Cl=1 | F=1 | N=5 | O=2
| smiles = COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
| StdInChI = 1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
| StdInChIKey = LVXJQMNHJWSHET-AATRIKPKSA-N
}}

达可替尼（INN：dacomtinib；商品名：Vizimpro）或译达克替尼，是一种治疗非小细胞肺癌（NSCLC）的药物。它是一种选择性且不可逆的表皮生长因子受体（EGFR）抑制剂。

达可替尼已进入多项III期临床试验。2014年1月首次试验的结果令人失望，未能达到研究目标。其他III期试验仍在进行中。

达可替尼于2018年9月在美国、2019年在日本、2019年在欧盟被批准用于医疗用途，用于治疗EGFR基因突变的非小细胞肺癌。

参考资料
外部链接
*